Candidiasis in the intensive care unit

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

In the last 2 decades, Candida species have progressed from infrequent pathogens to among the most important and frequent opportunistic microorganisms causing nosocomial infection in intensive care unit (ICU) patients. Medical and surgical ICUs have become the epicenter of the Candida epidemic. Superficial infections causing oropharyngeal and esophageal candidiasis are common, and, although non-life threatening, may be refractory to conventional antifungals. In contrast, invasive candidiasis, candidemia, and hematogenous disseminated infections are associated with considerable attributable mortality. Although blood isolates of C. albicans remain susceptible to fluconazole, the increasing incidence of non-albicans Candida species with intrinsic reduced susceptibility to azoles creates new therapeutic challenges. Fortunately, lipid formulations of amphotericin B and the recently introduced echinocandin group represent new and strategic treatment responses to the challenge of invasive candidiasis.

Original languageEnglish (US)
Pages (from-to)99-111
Number of pages13
JournalSeminars in Respiratory and Critical Care Medicine
Volume24
Issue number1
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Candidiasis
Candida
Invasive Candidiasis
Intensive Care Units
Echinocandins
Candidemia
Azoles
Fluconazole
Amphotericin B
Cross Infection
Infection
Lipids
Mortality
Incidence
Therapeutics

Keywords

  • Candida infections
  • Candidiasis
  • ICU

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Candidiasis in the intensive care unit. / Sobel, J. D.; Vazquez, Jose Antonio.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 24, No. 1, 01.02.2003, p. 99-111.

Research output: Contribution to journalReview article

@article{bedbcadfd00e4512bfb3db43deed5dc5,
title = "Candidiasis in the intensive care unit",
abstract = "In the last 2 decades, Candida species have progressed from infrequent pathogens to among the most important and frequent opportunistic microorganisms causing nosocomial infection in intensive care unit (ICU) patients. Medical and surgical ICUs have become the epicenter of the Candida epidemic. Superficial infections causing oropharyngeal and esophageal candidiasis are common, and, although non-life threatening, may be refractory to conventional antifungals. In contrast, invasive candidiasis, candidemia, and hematogenous disseminated infections are associated with considerable attributable mortality. Although blood isolates of C. albicans remain susceptible to fluconazole, the increasing incidence of non-albicans Candida species with intrinsic reduced susceptibility to azoles creates new therapeutic challenges. Fortunately, lipid formulations of amphotericin B and the recently introduced echinocandin group represent new and strategic treatment responses to the challenge of invasive candidiasis.",
keywords = "Candida infections, Candidiasis, ICU",
author = "Sobel, {J. D.} and Vazquez, {Jose Antonio}",
year = "2003",
month = "2",
day = "1",
language = "English (US)",
volume = "24",
pages = "99--111",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Candidiasis in the intensive care unit

AU - Sobel, J. D.

AU - Vazquez, Jose Antonio

PY - 2003/2/1

Y1 - 2003/2/1

N2 - In the last 2 decades, Candida species have progressed from infrequent pathogens to among the most important and frequent opportunistic microorganisms causing nosocomial infection in intensive care unit (ICU) patients. Medical and surgical ICUs have become the epicenter of the Candida epidemic. Superficial infections causing oropharyngeal and esophageal candidiasis are common, and, although non-life threatening, may be refractory to conventional antifungals. In contrast, invasive candidiasis, candidemia, and hematogenous disseminated infections are associated with considerable attributable mortality. Although blood isolates of C. albicans remain susceptible to fluconazole, the increasing incidence of non-albicans Candida species with intrinsic reduced susceptibility to azoles creates new therapeutic challenges. Fortunately, lipid formulations of amphotericin B and the recently introduced echinocandin group represent new and strategic treatment responses to the challenge of invasive candidiasis.

AB - In the last 2 decades, Candida species have progressed from infrequent pathogens to among the most important and frequent opportunistic microorganisms causing nosocomial infection in intensive care unit (ICU) patients. Medical and surgical ICUs have become the epicenter of the Candida epidemic. Superficial infections causing oropharyngeal and esophageal candidiasis are common, and, although non-life threatening, may be refractory to conventional antifungals. In contrast, invasive candidiasis, candidemia, and hematogenous disseminated infections are associated with considerable attributable mortality. Although blood isolates of C. albicans remain susceptible to fluconazole, the increasing incidence of non-albicans Candida species with intrinsic reduced susceptibility to azoles creates new therapeutic challenges. Fortunately, lipid formulations of amphotericin B and the recently introduced echinocandin group represent new and strategic treatment responses to the challenge of invasive candidiasis.

KW - Candida infections

KW - Candidiasis

KW - ICU

UR - http://www.scopus.com/inward/record.url?scp=0037325893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037325893&partnerID=8YFLogxK

M3 - Review article

C2 - 16088529

AN - SCOPUS:0037325893

VL - 24

SP - 99

EP - 111

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 1

ER -